Latest papers

Rate-limiting steps in hepatic drug clearance: comparison of hepatocellular uptake and metabolism with microsomal metabolism of saquinavir, nelfinavir, and ritonavir.

Phase I trial of the human immunodeficiency virus protease inhibitor nelfinavir and chemoradiation for locally advanced pancreatic cancer.

Quality control of protease inhibitors.

Uncomplicated outcome after an accidental overdose of nevirapine in a newborn.

HIV protease inhibitors provide neuroprotection through inhibition of mitochondrial apoptosis in mice.

Progress towards the use of HIV protease inhibitors in cancer therapy.

Drug-specific effect of nelfinavir and stavudine on primary culture of human preadipocytes.

Validation and toxicity of PI3K/Akt pathway inhibition by HIV protease inhibitors in humans.

Long-term safety and effectiveness of ritonavir, nelfinavir, and lopinavir/ritonavir in antiretroviral-experienced HIV-infected children.

Effect of CYP2C19 polymorphism on nelfinavir to M8 biotransformation in HIV patients.

Pharmacokinetics and pharmacodynamics of efavirenz and nelfinavir in HIV-infected children participating in an area-under-the-curve controlled trial.

Trace determination of ethyl methanesulfonate in Viracept 250 mg tablets by gas chromatography-mass spectrometry.

Safety and tolerability of depot medroxyprogesterone acetate among HIV-infected women on antiretroviral therapy: ACTG A5093

The contribution of naturally occurring polymorphisms in altering the biochemical and structural characteristics of HIV-1 subtype C protease.

Pharmacokinetic monitoring of HIV-1 protease inhibitors in the antiretroviral therapy.

Nelfinavir monotherapy increases naïve T-cell numbers in HIV-negative healthy young adults.

Drop in trough blood concentrations of tacrolimus after switching from nelfinavir to fosamprenavir in four HIV-infected liver transplant patients.

Significant decrease in nelfinavir systemic exposure after omeprazole coadministration in healthy subjects.

Synthesis, anti-HIV and antitubercular activities of nelfinavir diester derivatives.

Alterations in the Notch4 pathway in cerebral endothelial cells by the HIV aspartyl protease inhibitor, nelfinavir.